Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy

Frontiers in Medicine

article

Yuchen Qian¹  Lei Shi¹  Zhong Luo¹ 

[1] School of Life Sciences, Chongqing University

关键词: long non-coding RNAs;    cancer;    biomarker;    diagnosis;    prognosis;    therapy;   

DOI  :  10.3389/fmed.2020.612393

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Long non-coding RNAs (lncRNAs) are major components of cellular transcripts that are arising as important players in various biological pathways. They have received extensive attention in recent years, regarded to be involved in both developmental processes and various diseases. Due to their specific expression and functional diversity in a variety of cancers, lncRNAs have promising applications in cancer diagnosis, prognosis and therapy. Studies have shown that lncRNAs with high specificity and accuracy have the potential to become biomarkers in cancers. LncRNAs can be noninvasively extracted from body fluids, tissues and cells, and can be used as independent or auxiliary biomarkers to improve the accuracy of diagnosis or prognosis. Currently, the most well-recognized lncRNA is PCA3, which has been approved for use in the diagnosis of prostate cancer. Moreover, the underlying mechanisms of lncRNAs were explored as therapeutic targets, which have been investigated in clinical trials of several cancers. In this review, we presented a compilation of recent publications, clinical trials and patents, addressing the potential of lncRNAs that could be considered as biomarkers or therapeutic targets, with the hopes of providing promised implications for future cancer therapy.

【 授权许可】

CC BY